63
DRUG DISCOVERY & DEVELOPMENT RVS Chaitanya Koppala

Drug discovery and development

Embed Size (px)

Citation preview

Page 1: Drug discovery and development

DRUG DISCOVERY&

DEVELOPMENT

RVS Chaitanya Koppala

Page 2: Drug discovery and development

Introduction

In the past most drugs have been discovered either by identifying the active ingredient from traditional remedies or by serendipitous discovery.

But now we know diseases are controlled at molecular and physiological level.

Also shape of an molecule at atomic level is well understood.

Information of Human Genome

Page 3: Drug discovery and development

History of Drug Discovery :

Pre 1919• Herbal Drugs• Serendiptious discoveries

1920s, 30s• Vitamins• Vaccines

1940s• Antibiotic Era• R&D Boost due to WW2

1950s• New technology,• Discovery of DNA

1960s• Breakthrough in Etiology

1970s• Rise of Biotechnology• Use of IT

1980s• Commercialization of

Drug Discovery• Combinatorial Chemistry

1990s• Robotics• Automation

Page 4: Drug discovery and development

Registration:

The Ministry of health & Family Welfare and the Ministry of Chemicals & Fertilizers have major role in regulation of IPM.

NDA must be submitted to DCGI Phase III study reported to CDL, Kolkata Package inserted approved by DCI Marketing approval from FDA

Page 5: Drug discovery and development

~$800 M spent to bring a new drug to market.

$182 Billion spent on Pharma R&D in 2016

Share of CROs in research operations is 27%

World CRO market is 16.3 B (Indian share $500 M)

Market Scenerio:

Page 6: Drug discovery and development

Top CROs (By Revenue)

Contract Research Organizations Firm focus on Quintiles Clinical development to marketing

Covance Clinical research

Parexel Biopharma, medical devices, diagnostics

InVentiv Health Clinical development to marketing

Icon Genomic sciences and oncology

PRA Health Sciences Biologics and bioanalytics

PPD Drug development process

Charles River Laboratories Pharmaceutical and agricultures services

Chiltern Clinical data managment

INC research Late stage clinical trials

Page 7: Drug discovery and development

Top CROs (India)

Contract Research Organizations LocationActimus Biosciences Hyderabad

Advinus Therapeutics Bangalore

Aurigene Discovery technologies Bangalore

Chembiotek Kolkata

GVK Biosciences Hyderabad

Jubilant Organosys Bangalore

Ranbaxy Life Sciences Mumbai

Reliance Life Sciences Mumbai

Suven Life Sciences Hyderabad

Syngene Bangalore

Page 8: Drug discovery and development

Most valuable R&D Projects

Rank Product Company Phase Pharmacological class Today's NPV($mn)

1 Degludec Novo Nordisk Phase III Insulin 5,807

2 Tofacitinib Pfizer Phase III JAK-3 inhibitor 4,953

3 BG-12 Biogen Idec Phase III Fumarate 4,666

4 Incivek J & J Phase IV Hep C protease inhibitor 4,332

5 Relovair Theravance Phase III Corticosteroid 4,241

6 DR Cysteamine Undisclosed Phase III Lysosomal transport modulator 4,155

7 AMR 101 Undisclosed Phase III Omega-3 fatty acid 4,052

8 Eliquis Bristol Myers Squibb Phase IV Factor Xa inhibitor 3,836

9 Eliquis Pfizer Phase IV Factor Xa inhibitor 3,592

10 Bexssero Novartis Phase IV Meningococcal B vaccine 3,250

Page 9: Drug discovery and development

Top Companies by R&D Expense:

Sr. No. Company R & D spend ($bn) ,20101 Novartis 7.92 Merck & Co 8.13 Roche 7.84 GlaxoSmithKline 5.75 Sanofi 5.86 Pfizer 9.17 Johnson & Johnson 4.58 Eli Lilly 4.79 AstraZeneca 4.2

10 Takeda 3.411 Bayer 2.312 Bristol-Myers Squibb 3.313 Boehringer Ingelheim 3.114 Amgen 2.815 Novo Nordisk 1.7

Page 10: Drug discovery and development

Drug Development Cost Break-upR&D Function %

Discovery/Basic Research

Synthesis & Extraction 10.0

Biological Screening & testing 14.2

Preclinical Testing

Toxicology & Safety testing 4.5

Pharmaceutical Dosage Formulation 7.3

Clinical Trials

Phase I, II, III 29.1

Phase IV 11.7

Manufacturing & QC 8.3

IND & NDA 4.1

Bioavailability 1.8

Others 9.0

Total 100.0

Page 11: Drug discovery and development

10,000COMPOUNDS

250COMPOUNDS 5 COMPOUNDS

1 FDA APPROVED

DRUG

~6.5 YEARS ~7 YEARS ~1.5 YEARS

DRUG DISCOVERY

PRECLINICAL

CLINICAL TRIALS FDAREVIEW

Drug Discovery & Development-Timeline

Page 12: Drug discovery and development

Drug Discovery

Drugs Discovery methods:Random ScreeningMolecular ManipulationMolecular DesigningDrug MetabolitesSerendipity

Page 13: Drug discovery and development

Target Selection

• Cellular and Genetic Targets

• Genomics

• Proteomics

• Bioinformatics

Lead Discovery

• Synthesis and Isolation

• Combinatorial Chemistry

• Assay development

• High-Throughput Screening

Medicinal Chemistry

• Library Development

• SAR Studies

• In Silico Screening

• Chemical Synthesis

In Vitro Studies

• Drug Affinity and Selectivity

• Cell Disease Models

• MOA

• Lead Candidate Refinement

In Vivo Studies

• Animal models of Disease States

• Behavioural Studies

• Functional Imaging

• Ex-Vivo Studies

Clinical Trials and

Therapeutics

Page 14: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Cellular & Genetic Targets

Genomics

Proteomics

Bioinformatics

Target Selection

The decision to focus on finding an agent with a particular biological action that is anticipated to have therapeutic utility.

Target identification: targets that are involved in disease progression.

Target validation: to prove that manipulating the molecular target can provide therapeutic benefit for patients.

Page 15: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Cellular & Genetic Targets

Genomics

Proteomics

Bioinformatics

Target SelectionBiochemical Classes of Drug Targets

G-protein coupled receptors - 45%

Enzymes - 28%

Hormones and factors - 11%

Ion channels - 5%

Nuclear receptors - 2%

Techniques for Target Identification

Page 16: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Cellular & Genetic Targets

Genomics

Proteomics

Bioinformatics

Cellular & Genetic Targets: Involves the identification of the function of a potential therapeutic drug target

and its role in the disease process.

For small-molecule drugs, this step in the process involves identification of the target receptors or enzymes

Where as for some biologic approaches the focus is at the gene or transcription level.

Drugs usually act on either cellular or genetic chemicals in the body, known as targets, which are believed to be associated with disease.

Page 17: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Cellular & Genetic Targets

Genomics

Proteomics

Bioinformatics

Genomics:The study of genes and their function. Genomics aims to understand the structure of the genome, including the mapping genes and sequencing the DNA.

Seeks to exploit the findings from the sequencing of the human and other genomes to find new drug targets.

Human Genome consists of a sequence of around 3 billion nucleotides (the A C G T bases) which in turn probably encode 35,000 – 50,000 genes. 

Page 18: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Cellular & Genetic Targets

Genomics

Proteomics

Bioinformatics

Genomics: Drew’s et al estimates that the number of genes implicated in

disease, both those due to defects in single genes and those arising from combinations of genes, is about 1,000

He proposes that the number of potential drug targets may lie between 5,000 and 10,000.

Single Nucleotide Polymorphism (SNP) libraries: are used to compare the genomes from both healthy and sick people and to identify where their genomes vary.

Page 19: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Cellular & Genetic Targets

Genomics

Proteomics

Bioinformatics

Proteomics: It is the study of the proteome, the complete set of proteins

produced by a species, using the technologies of large – scale protein separation and identification.

It is also at the protein level that disease processes become manifest, and at which most (91%) drugs act.

  Therefore, the analysis of proteins (including protein-protein,

protein-nucleic acid, and protein ligand interactions) will be utmost importance to target discovery.

Page 20: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Cellular & Genetic Targets

Genomics

Proteomics

Bioinformatics

Proteomics: Proteomics is the systematic high-throughput separation and

characterization of proteins within biological systems.

Target identification with proteomics is performed by comparing the protein expression levels in normal and diseased tissues.

2D PAGE is used to separate the proteins, which are subsequently identified and fully characterized with LC-MS/MS.

Page 21: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Cellular & Genetic Targets

Genomics

Proteomics

Bioinformatics

Bioinformatics:Bioinformatics is a branch of molecular biology that involves extensive analysis of biological data using computers, for the purpose of enhancing biological research.

It plays a key role in various stages of the drug discovery process including

Target identification

Computer screening of chemical compounds

Pharmacogenomics

  

Page 22: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Cellular & Genetic Targets

Genomics

Proteomics

Bioinformatics

Bioinformatics: Bioinformatics methods are used to transform the raw sequence

into meaningful information

Can compare the entire genome of pathogenic and non-pathogenic strains of a microbe

Using gene expression micro arrays and gene chip technologies,

single device can be used to evaluate and compare the expression of up to 20000 genes of healthy and diseased individuals at once

Page 23: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Synthesis and Isolation

Combinatorial Chemistry

Assay Development

High Throughput Screening

Lead Discovery: Identification of small molecule modulators

of protein function The process of transforming these into high-

content lead series.

Page 24: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Synthesis and Isolation

Combinatorial Chemistry

Assay Development

High Throughput Screening

Synthesis and Isolation: Separation of mixture Separation of impurities In vitro chemical synthesis Biosynthetic intermediate

Page 25: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Synthesis and Isolation

Combinatorial Chemistry

Assay Development

High Throughput Screening

Combinatorial Chemistry:Rapid synthesis of or computer simulation of large no. of

different but structurally related molecules Search new leads Optimization of target affinity & selectivity. ADME properties Reduce toxicity and eliminate side effects

Page 26: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Synthesis and Isolation

Combinatorial Chemistry

Assay Development

High Throughput Screening

Assay Development• Used for measuring the activity of a drug.• Discriminate between compounds.• Evaluate:• Expressed protein targets.• Enzyme/ substrate interactions.

Page 27: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Synthesis and Isolation

Combinatorial Chemistry

Assay Development

High Throughput Screening

High throughput screening: Screening of drug target against selection of

chemicals. Identification of highly target specific

compounds.

Page 28: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Synthesis and Isolation

Combinatorial Chemistry

Assay Development

High Throughput Screening

High throughput screening:

Page 29: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Library Development

SAR Studies

In Silico Screening

Chemical Synthesis

Medicinal Chemistry: It’s a discipline at the intersection of synthetic

organic chemistry and pharmacology. Focuses on small organic molecules (and not on

biologics and inorganic compounds) Used in• Drug discovery (hits)• Lead optimization (hit to lead)• Process chemistry and development

Page 30: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Library Development

SAR Studies

In Silico Screening

Chemical Synthesis

Library Development: Collection of stored chemicals along with

associated database. Assists in High Throughput Screening Helps in screening of drug target (hit) Based on organic chemistry

Page 31: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Library Development

SAR Studies

In Silico Screening

Chemical Synthesis

SAR Studies: Helps identify pharmacophore The pharmacophore is the precise section of

the molecule that is responsible for biological activity

Enables to prepare more active compound Allow elimination of excessive functionality

Page 32: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Library Development

SAR Studies

In Silico Screening

Chemical Synthesis

SAR Studies:

Morphine Molecule

Page 33: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Library Development

SAR Studies

In Silico Screening

Chemical Synthesis

In silico screening: Computer simulated screening of chemicals Helps in finding structures that are most

likely to bind to drug target. Filter enormous Chemical space Economic than HTS

Page 34: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Library Development

SAR Studies

In Silico Screening

Chemical Synthesis

Chemical Synthesis: Involve production of lead compound in suitable

quantity and quality to allow large scale animal and eventual, extensive human clinical trials

Optimization of chemical route for bulk industrial production.

Suitable drug formulation

Page 35: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Drug Affinity and Selectivity

Cell Disease Models

MOA

Lead Candidate

Refinement

In Vitro Studies: (In glass) studies using component of organism i.e. test tube

experiments (simulated experiments) Examples-

• Cells derived from multicellular organisms• Subcellular components (Ribosomes, mitochondria)• Cellular/ subcellular extracts (wheat germ, reticulocyte

extract)• Purified molecules (DNA,RNA)

Page 36: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Drug Affinity and Selectivity

Cell Disease Models

MOA

Lead Candidate

Refinement

In Vitro Studies:Advantages:

• Studies can be completed in short period of time.• Reduces risk in post clinical trials • permits an enormous level of simplification of the system • investigator can focus on a small number of components

Page 37: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Drug Affinity and Selectivity

Cell Disease Models

MOA

Lead Candidate

Refinement

Drug affinity and selectivity• Drug affinity is the ability of drug to bind to its biological

target (receptor, enzyme, transport system, etc.)

• Selectivity- Drug should bind to specific receptor site on the cell (eg. Aspirin)

Page 38: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Drug Affinity and Selectivity

Cell Disease Models

MOA

Lead Candidate

Refinement

• Isogenic human disease models- are a family of cells that are selected or engineered to accurately model the genetics of a specific patient population, in vitro

• Stem cell disease models-Adult or embryonic stem cells carrying or induced to carry defective genes can be investigated in vitro to understand latent molecular mechanisms and disease characteristics

Cell disease models

Page 39: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Drug Affinity and Selectivity

Cell Disease Models

MOA

Lead Candidate

Refinement

Optimizing chemical hits for clinical trial is commonly referred to as lead optimization

The refinement in structure is necessary in order to improve • Potency• Oral Availability• Selectivity• Pharmacokinetic properties• Safety (ADME properties)

Lead Candidate refinement

Page 40: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Animal models of Disease States

Behavioural Studies

Functional Imaging

Ex-Vivo Studies

In vivo studies

Its experimentation using a whole, living organism. Gives information about,• Metabolic profile• Toxicology• Drug interaction

Page 41: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Animal models of Disease States

Behavioural Studies

Functional Imaging

Ex-Vivo Studies

Animal models of disease states Test conditions involving induced disease or

injury similar to human conditions. Must be equivalent in mechanism of cause. Can predict human toxicity in 71% of the cases. Eg. SCID mice-HIV

NOD mice- DiabetesDanio rerio- Gene function

Page 42: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Animal models of Disease States

Behavioural Studies

Functional Imaging

Ex-Vivo Studies

Behavioural Studies Tools to investigate behavioural results of drugs. Used to observe depression and mental disorders. However self esteem and suicidality are hard to induce. Example:

Despair based- Forced swimming/ Tail suspension Reward based Anxiety Based

Page 43: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Animal models of Disease States

Behavioural Studies

Functional Imaging

Ex-Vivo Studies

Functional Imaging: Method of detecting or measuring changes in

metabolism, blood flow, regional chemical composition, and absorption.

Tracers or probes used. Modalities Used-

MRI CT-Scan

Page 44: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Animal models of Disease States

Behavioural Studies

Functional Imaging

Ex-Vivo Studies

Ex-Vivo Studies: Experimentation on tissue in an artificial

environment outside the organism with the minimum alteration of natural conditions.

Counters ethical issues. Examples:

Measurement of tissue properties Realistic models for surgery

Page 45: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Phase-I

Phase-II

Phase-III

Phase-IV

Clinical trials: An investigational new drug application (IND) : outlines what the

sponsor of a new drug proposes for human testing in clinical trials. Phase 0 Phase I studies Phase II studies Phase III studies Submission of New Drug Application (NDA) is the formal step asking

the FDA to consider a drug for marketing approval. FDA reviewers will approve the application or find it either "approvable" or "not approvable." Phase IV studies

Page 46: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Phase-I

Phase-II

Phase-III

Phase-IV

Page 47: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Phase-I

Phase-II

Phase-III

Phase-IV

Page 48: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Phase-I

Phase-II

Phase-III

Phase-IV

Page 49: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Phase-I

Phase-II

Phase-III

Phase-IV

Phase 0: Study of new drug in microdoses to derive PK information in human

before undertaking phase I studies is called PHASE O

Microdose: Less than 1/100 of the dose of a test substance calculated to produce pharmacological effect with a max dose ≤100 micrograms

Objective: To obtain preliminary Pharmacokinetic data.

Preclinical Data: Subacute toxicity study in one species by two routes of administration.

Page 50: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Phase-I

Phase-II

Phase-III

Phase-IV

Phase I: Clinical Pharmacologic Evaluation First stage of testing in human subjects. 20-50 Healthy Volunteers Concerned With:– Human Toxicity and Tolerated Dosage Range– Pharmacokinetics– Pharmacology/dynamics

Page 51: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Phase-I

Phase-II

Phase-III

Phase-IV

Phase I:Types of Phase-I Trials• SAD (Single Ascending Dose)• MAD (Multiple Ascending Dose)• Food effect

Page 52: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Phase-I

Phase-II

Phase-III

Phase-IV

Phase II:• Controlled Clinical Evaluation.• 50-300 Patients• Controlled Single Blind Technique• Concerned With:

– Safety– Efficacy– Drug Toxicity– Drug Interaction

Page 53: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Phase-I

Phase-II

Phase-III

Phase-IV

Phase II Types: Phase IIA: Designed to assess dosing requirements Phases IIB: Designed to study efficacy

Phase IIA Phase IIBEARLY PHASE LATE PHASE Pilot clinical trials Pivotal clinical trials 20-200 PATIENTS 50-300 PATIENTS Not multicentric MulticentricSINGLE BLIND comparison with a standard drug

DOUBLE BLIND compared with a placebo or standard drug

Page 54: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Phase-I

Phase-II

Phase-III

Phase-IV

Phase III:• Extended Clinical Trials.• Most expensive & time consuming.• 250-1000 Patients.• Controlled Double Blind Technique.• Concerned With:

– Safety, Efficacy– Comparison with other Drugs– Package Insert

Page 55: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Phase-I

Phase-II

Phase-III

Phase-IV

Phase IIIa Phase IIIb Prior to NDA After the NDA but prior to the approval

and launch. Generates data on safety and efficacy These may supplement or complete the

earlier trials or may be directed to Phase IV trials

Phase III Studies : End of Clinical Trial Activities

Sponsor: Expert Committee review of Efficacy, safety and potential sales (Profit). Go-No Go decision to file new drug application with DCGI Expert review by DCGI’s Committee DCGI approval NCE marketed :Phase IV begins

Page 56: Drug discovery and development

Target Selection Lead Discovery

Medicinal Chemistry

In Vitro Studies

In Vivo Studies

Clinical Trials

Phase-I

Phase-II

Phase-III

Phase-IV

Phase IV:• Post Marketing Surveillance.• Designed to detect any rare or long-term

adverse effects.• Adverse Drug Reaction Monitoring.• Pharmacovigilance.

Page 57: Drug discovery and development

10,000COMPOUNDS

250COMPOUNDS 5 COMPOUNDS

1 FDA APPROVED

DRUG

~6.5 YEARS ~7 YEARS ~1.5 YEARS

DRUG DISCOVERY

PRECLINICAL

CLINICAL TRIALS FDAREVIEW

Drug Discovery & Development-Timeline

Page 58: Drug discovery and development

Gene Therapy

• Technique for correcting defective genes.

• It is the process of inserting genes into cells to treat diseases.

• Gene therapy is used to correct a deficient phenotype.

Page 59: Drug discovery and development

Gene Therapy-Approaches

Germ line Gene Therapy Sperm or eggs, are modified by the introduction of functional genes, which are

integrated into their genomes.

Change would be heritable and would be passed on to later generations.

Somatic Gene Therapy The therapeutic genes are transferred Into the somatic cells of a patient.

Change will not be inherited by the patient's offspring or later generations.

Page 60: Drug discovery and development

Gene Therapy- Types

Ex Vivo Gene Therapy Transfer of therapeutic genes in cultured cells which are then

reintroduced into patient.

In Vivo Gene Therapy The direct delivery of genes into the cells of a particular

tissue is referred to as in vivo gene therapy.

Page 61: Drug discovery and development

Gene Therapy- Vectors

• VirusesRetrovirusesAdenovirusesAdeno-associated virusesHerpes Simplex viruses

• Pure DNA Constructs• Lipoplexes• DNA Molecular Conjugates• Human Artificial Chromosome

Page 62: Drug discovery and development

Recent Developments

• Nanotechnology + gene therapy yielded treatment to torpedo cancer

• Results of world's first gene therapy for inherited blindness show sight improvement

• New Method of Gene Therapy Alters Immune Cells for Treatment of Advanced Melanoma

• Dual Gene Therapy Suppresses Lung Cancer in Preclinical Test

Page 63: Drug discovery and development

Thank you